MetaCap

Kiora Pharmaceuticals (KPRX) vs NeuroSense Therapeutics (NRSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeuroSense Therapeutics is the larger company by market cap ($3.2 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KPRX-71.53%NRSN-66.49%
+5%-35%-75%
Oct 7, 20261 yearNov 20, 2026
KPRX-71.65%NRSN-65.03%
+4%-36%-75%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KPRX versus NRSN key metrics
MetricKPRXNRSN
Share price$0.7202$1.28
Market cap$3.19M$3.19M
1-day change-12.28%+1.59%
YTD return-63.44%—
1-year return-61.49%—
5-year return-99.87%—
EPS (TTM)$-2.72$-47.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-10.84M$-11.13M
52-week high$2.91$24.80
52-week low$0.72$1.10
Distance from 52-week high-75.25%-94.84%
Analyst consensusnonestrong_buy
Avg. price target upside+1566.20%+7503.91%
Average volume35.23K31.57K
Shares outstanding4.42M2.49M
Employees1317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About NeuroSense Therapeutics

NRSN stock →

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

KPRX vs NRSN FAQ

Which is bigger, Kiora Pharmaceuticals or NeuroSense Therapeutics?

NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $3.19M compared with $3.19M for Kiora Pharmaceuticals (KPRX).

Are Kiora Pharmaceuticals and NeuroSense Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons